在HOPE-B iii期试验中，接受dezaparvovec的重度或中度血友病B成人患者在24个月的随访后，平均因子IX活性水平稳定增加，并具有持久的止血保护作用

{"title":"在HOPE-B iii期试验中，接受dezaparvovec的重度或中度血友病B成人患者在24个月的随访后，平均因子IX活性水平稳定增加，并具有持久的止血保护作用","authors":"W. S. Pipe, WG F Leebeek, M. Recht, S. Key, S. Lattimore, G. Castaman, M. Coppens, D. Cooper, R. Gut, S. Slawka, S. Verweij, R. Dolmetsch, Y. Li, P. Monahan, W. Miesbach","doi":"10.1055/s-0042-1760523","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":217767,"journal":{"name":"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark","volume":"24 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up\",\"authors\":\"W. S. Pipe, WG F Leebeek, M. Recht, S. Key, S. Lattimore, G. Castaman, M. Coppens, D. Cooper, R. Gut, S. Slawka, S. Verweij, R. Dolmetsch, Y. Li, P. Monahan, W. Miesbach\",\"doi\":\"10.1055/s-0042-1760523\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":217767,\"journal\":{\"name\":\"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark\",\"volume\":\"24 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0042-1760523\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1760523","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}